ArticleCureus2025
The Association of Plasma Osmolarity With No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The no-reflow phenomenon is a serious complication that can occur after primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI), leading to poor myocardial reperfusion and adverse outcomes. Objective This study aims to evaluate the association between admission plasma osmolarity and the occurrence of the no-reflow phenomenon in patients with STEMI undergoing primary PCI. Methods This retrospective cohort study was conducted at Shalamar Hospital, Lahore, Pakistan from February 2022 to February 2025. The study included 486 consecutive patients diagnosed with STEMI who underwent primary PCI. Patients aged ≥ 18 years, confirmed diagnosis of STEMI based on chest pain duration of more than 30 minutes, ST-segment elevation of ≥1 mm in at least two contiguous ECG leads, and elevated cardiac biomarkers were included in the study. Results In this study of 486 STEMI patients undergoing primary PCI, high plasma osmolarity (>295 mOsm/L) was significantly associated with an increased incidence of no-reflow (31.1%) compared to normal (13.4%) and low osmolarity groups (9.2%). The incidence of no-reflow was significantly higher in the high osmolarity group (31.1%) compared to the normal (13.4%) and low (9.2%) groups (p < 0.001). High plasma osmolarity was independently associated with an increased risk of no-reflow (adjusted odds ratio 2.94; 95% CI: 1.61-5.38; p < 0.001). Conclusion It is concluded that elevated plasma osmolarity is an independent predictor of the no-reflow phenomenon in STEMI patients undergoing primary PCI. Routine assessment of plasma osmolarity may offer a simple and effective method for early risk stratification, with potential implications for personalized management strategies to improve reperfusion outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.